Rosiglitazone (Maleate)
Rosiglitazone (Maleate) is an oral hypoglycaemic agent belongs to thiazolidinedione class, used to treat type II (non-insulin dependent) diabetes mellitus. It reduces peripheral insulin resistance, leading to a reduction of blood-glucose concentration. Rosiglitazone (Maleate) is used either alone or in combination with metformin or with sulfonyl urea.
Primary Characteristics
It is of Synthetic origin and belongs to Thiazolidinedione.
Molecular Weight: 473.52 · pKa: 6.8, 6.1 · Solubility in Alcohol: readily soluble · Non-proprietary name: Rosiglitazone (Maleate).
Pharmacokinetics
Distribution: Rosiglitazone (Maleate) has a volume of distribution is 0.25(0.17-0.33)l/kg. plasma protein binding is 99.8%.
Elimination: plasma half-life is 3.5(3-4)hr, renal excretion is negligible.
Advertisement
Indications
Rosiglitazone (Maleate) is primarily indicated in conditions like NIDDM, Type II diabetes mellitus.
Contraindications
Rosiglitazone (Maleate) is contraindicated in conditions like Diabetic ketoacidosis, Hypersensitivity.
Dosage
Rosiglitazone (Maleate)'s dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 4 mg | 4 mg | Every 24h | PO | For patients who respond inadequately following 12 weeks of treatment, the dose may be increased to 8 mg administered as single dose or in divided doses twice daily |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Rosiglitazone (Maleate) in overdosage may give rise to further complications which include Hypercholesterolemia, Congestive heart failure , Hypoglycemia, Anaemia , Cardiac hypertrophy, Oedema , Fluid retension .
Rosiglitazone (Maleate) is known to cause more or less tolerable side effects which are usually transient. These include Weight gain.
Warnings / Precautions
Interference in Pathology
Rosiglitazone (Maleate) may interfere in the diagnosis of Hematocrit Value , Increases ALT levels.
Available Brands
Storage Conditions
Drug Classification
- 1.18.7.2 — Oral hypoglycemics